At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Erlotinib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of EGFR Inhibition With Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating Erlotinib, Erlotinib Hydrochloride, and 2 other interventions for Cirrhosis and Hepatocellular Carcinoma. Completed, enrolled 25 participants across 6 sites.
Detailed Summary
This pilot phase I/II trial studies the best dose of erlotinib hydrochloride and to see how well it works in preventing liver cancer in patients with scarring (cirrhosis) of the liver. Erlotinib hydrochloride may help to inhibit the development of fibrous tissue and prevent liver cancer from forming in patients with cirrhosis of the liver.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCirrhosis, Hepatocellular Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2014
Primary CompletionFeb 2020
Study CompletionMar 2022
TodayJul 2026
First PostedOct 24, 2014
Enrollment StartNov 24, 2014
Primary CompletionFeb 11, 2020
Study CompletionMar 10, 2022
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 11.7 years ago
Interventions
Erlotinibdrug
Given PO
Erlotinib Hydrochloridedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Quality-of-Life Assessmentother
Ancillary studies